Eli Lilly (LLY) Non-Current Deferred Tax Liability (2009 - 2022)

Eli Lilly has reported Non-Current Deferred Tax Liability for 11 years, with the latest figure at $4.6 billion in Q4 2022.

• For the quarter ending Q4 2022, Non-Current Deferred Tax Liability rose 164.12% year-over-year to $4.6 billion; the trailing twelve-month figure through Dec 2022 stood at $4.6 billion (up 164.12% YoY), and the FY2022 full-year result was $4.6 billion, up 164.12% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2022 stood at $4.6 billion, up from $171.9 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $5.1 billion in Q4 2020, with the low at $171.9 million in Q3 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $2.4 billion across 5 years, with a median of $2.2 billion in 2020.
• The largest YoY upside for Non-Current Deferred Tax Liability was 164.12% in 2022 against a maximum downside of 89.47% in 2022.
• Eli Lilly's Non-Current Deferred Tax Liability stood at $3.0 billion in 2018, then soared by 51.61% to $4.6 billion in 2019, then gained by 10.13% to $5.1 billion in 2020, then plunged by 65.81% to $1.7 billion in 2021, then jumped by 164.12% to $4.6 billion in 2022.
• The last three Non-Current Deferred Tax Liability figures came in at $4.6 billion (Q4 2022), $171.9 million (Q3 2022), and $862.5 million (Q2 2022), per Business Quant data.